Cadila Pharmaceuticals, one of India’s most respected and research-driven pharmaceutical companies, has launched Vasograin Plus, a novel, dual-action formulation designed for the acute treatment of migraines with or without aura in both adults and adolescents.

Vasograin Plus represents a major advancement in the treatment of migraine, a condition that affects millions globally and significantly influences quality of life. It is a unique therapy that combines two well-established pharmacological agents to work through complementary mechanisms, targeting both the neurological and inflammatory triggers of migraines. It delivers rapid onset of action, longer-lasting relief, and helps reduce the likelihood of recurrence, all in a single tablet.

Dr. Rajiv I. Modi, Chairman & Managing Director of Cadila Pharmaceuticals Limited, said, “At Cadila Pharmaceuticals, we believe healthcare should not just treat, but empower. Vasograin Plus is the result of rigorous science, patient needs, and our unwavering focus on innovation. With its launch, we reaffirm our commitment to helping people live healthier, fuller lives, free from the limitations imposed by chronic conditions like migraine.”

Vasograin Plus combines the benefits of a selective serotonin receptor agonist and a non-steroidal anti-inflammatory agent to provide dual-action relief. It effectively addresses the neurological impact by helping constrict dilated cranial blood vessels and inhibiting the pain signals triggered by the trigeminal nerve, and reducing inflammation and pain sensitivity that often prolong migraine symptoms.

Vasograin Plus offers a new sense of control and confidence for people living with episodic or recurrent migraines. It enhances patient compliance and improves outcomes by simplifying treatment through a fixed-dose combination and eliminating the need for multiple medications.